Evotec Reports Mixed 2025 Results, Issues Significantly Lower 2026 Guidance Amidst Major Transformation
EVO sits 17% above its 52-week low of $2.308.
Summary
Evotec SE announced 2025 financial results at the high end of guidance but provided a significantly reduced outlook for 2026, signaling a transitional year focused on a major operating model transformation.
Key Events · Earnings and Guidance · EVO
-
2025 Financial Performance
Reported full-year 2025 group revenues of €788.4 million and adjusted group EBITDA of €41.1 million, exceeding prior guidance.
-
Significantly Lower 2026 Guidance
Issued a challenging outlook for 2026, projecting group revenues of €700-780 million and adjusted EBITDA of €0-40 million, a substantial reduction from 2025.
-
Major Operating Model Transformation
Detailed the "Horizon" transformation, aiming for €75 million in structural run-rate cost savings by the end of 2027, with initial financial benefits expected in the second half of 2026.
-
Strategic Milestones & Divestiture
Highlighted several milestone payments from partnerships and reiterated the expected ~$100 million upfront from the Tubulis sale to Gilead Sciences, which was previously announced on April 7, 2026.
Analysis · EVO · Life Sciences
Evotec SE reported strong 2025 Adjusted EBITDA, exceeding guidance, and highlighted significant milestone payments and the Tubulis divestiture. However, the company issued substantially lower guidance for 2026, projecting a "transition year" with group revenues of €700-780 million and adjusted EBITDA of €0-40 million, a notable decrease from 2025. This challenging short-term outlook is driven by the ongoing "Horizon" operating model transformation, which aims for €75 million in structural cost savings by late 2027 but will impact 2026 profitability. Investors will likely focus on the challenging near-term guidance, despite the long-term strategic benefits of the transformation and positive leadership changes.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVO was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $920.7M. The 52-week trading range was $2.31 to $4.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.